Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RAF1
REST API REST API
Homo sapiens
RAF1 is differentially expressed in 261 experiments: 138 organism parts: placenta, cerebellum, ... (136 more);, 159 disease states: normal, glioblastoma, ... (157 more);, 84 cell types 309 cell lines 34 compound treatments and 76 other conditions.
Synonyms c-Raf, Raf-1, CRAF
Orthologs F6U6W3_CIOIN (Ciona intestinalis)   raf1a (Danio rerio)   RAF1_CHICK (Gallus gallus)   Raf1 (Mus musculus)   raf1b (Danio rerio)   phl (Drosophila melanogaster)   Raf1 (Rattus norvegicus)   raf1 (Xenopus laevis)   RAF1 (Bos taurus)   RAF1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, receptor signaling protein activity, cytoskeleton organization, protein binding, apoptosis, cytoplasm, cell proliferation, epidermal growth factor receptor signaling pathway, negative regulation of cell proliferation, MAP kinase kinase kinase activity, negative regulation of apoptosis, MAPKKK cascade, metal ion binding, protein tyrosine kinase activity, insoluble fraction, insulin receptor signaling pathway, blood coagulation, response to hypoxia, mitochondrial outer membrane, activation of MAPKK activity, ATP binding, Ras protein signal transduction, axon guidance, small GTPase mediated signal transduction, synaptic transmission, heart development, protein heterodimerization activity, nucleotide binding, protein serine/threonine kinase activity, signal transduction, protein kinase activity, pseudopodium, positive regulation of peptidyl-serine phosphorylation, Ras GTPase binding, nerve growth factor receptor signaling pathway, mitogen-activated protein kinase kinase binding, platelet activation, negative regulation of protein complex assembly, protein phosphorylation, intracellular signal transduction
InterPro Term Prot_kinase_cat_dom, Raf-like_ras-bd, Prot_Kinase_C-like_PE/DAG-bd, DAG/PE-bd, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession P04049, B4E0X2, B4E1N6
Gene-Disease Assocation LEOPARD SYNDROME 2, NOONAN SYNDROME 5; NS5
Search EB-eye ENSG00000132155
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (37 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
BT474
2
E-MEXP-440, E-MTAB-62
HCC38
2
E-MTAB-37, E-MTAB-62
HL-60
2
E-MTAB-37, E-GEOD-24147
MOLT4
2
E-MTAB-62, E-MTAB-37
T84
2
E-GEOD-1474, E-MTAB-37
303 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-19397, E-GEOD-3920, ... (41 experiments)

Factor Value U/D Experiments
stromal cell
2
E-GEOD-10797, E-GEOD-1460
memory B cell
2
E-MEXP-2360, E-TABM-702
macrophage
1
2
E-GEOD-22373, E-GEOD-3982, E-GEOD-360
endothelial cell
1
2
E-GEOD-19240, E-GEOD-96, E-GEOD-3920
CD16+ dendritic cell
1
1
E-TABM-34
CXCR4 positive
1
E-GEOD-15893
78 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (50 experiments)

Factor Value U/D Experiments
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
breast carcinoma
2
E-TABM-276, E-GEOD-5823
Burkitt's lymphoma
2
E-GEOD-1880, E-MTAB-37
Duchenne muscular dystrophy
2
E-GEOD-3307, E-GEOD-1004
lung adenocarcinoma
2
E-GEOD-2514, E-MTAB-62
prostate carcinoma
1
2
E-MEXP-2034, E-GEOD-96, E-MTAB-62
153 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-5741, E-GEOD-1417, E-GEOD-5824, E-MEXP-1958, ... (23 experiments)

Factor Value U/D Experiments
vanadium pentoxide
1
E-GEOD-5339
selenium
1
E-MEXP-1327
filtered air
1
E-TABM-127
CNOT7+CNOT8
1
1
E-MEXP-2218
unknown
1
E-GEOD-7307
HMB-PP (phosphoantigen)
1
1
E-MEXP-1601
28 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-2191, E-GEOD-21374, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-3140, E-MEXP-2359

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-21138, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (6 experiments)

Genotype
studied in E-TABM-1029, E-TABM-36, E-GEOD-2466, E-GEOD-17476, E-GEOD-2292, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-6432, E-GEOD-7011, E-TABM-127, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-2466, E-GEOD-1926, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12254

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84 ... (5 experiments)

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-GEOD-1676, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-19743, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

tissue type
studied in E-GEOD-29580

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.417 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM